Sector News

Illumina Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics

July 21, 2015
Life sciences
(BUSINESS WIRE) – Illumina Inc.  today announced that Sanjay Chikarmane has been named Senior Vice President and General Manager of Illumina’s Enterprise Informatics business. Chikarmane will lead the development and commercialization of products and services aimed at turning genomic data into actionable information for researchers and clinicians. He will report to Illumina President, Francis deSouza.
 
“Given the growing data intensive demands of the genomics market, we felt it critical to bring in a group leader dedicated to driving our informatics strategy,” said Francis deSouza, President of Illumina. “Sanjay is an excellent addition to Illumina’s leadership team and will be instrumental in growing our enterprise informatics business, defining our software development processes and service delivery architecture that will be used across all of Illumina.”
 
Nick Naclerio who led the acquisition of NextBio and served as the founding General Manager of the Enterprise Informatics business unit will return to the full-time role of Senior Vice President of Corporate Development.
 
Chikarmane joins Illumina with more than 20 years of experience in enterprise software at companies including HP, BEA Systems and most recently, SAP. Through his career, he has held a variety of leadership roles in enterprise software, including general management, go-to-market, product management and product development, during which he has successfully created and scaled several market leading products. While at SAP, Chikarmane oversaw several key products including industry solutions for big data analytics on the HANA platform, cloud business networks, data management and middleware, including their adoption by top customers.
 
Chikarmane holds a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology (IIT), Bombay, India and a Master of Science in Computer Engineering from Syracuse University.
 
Source: Illumina

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend